Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Ipilimumab +/- Nivolumab in Advanced Tumors
NCT04311710Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of ipilimumab in melanoma, urothelial carcinoma (UC), hepatocellular carcinoma (HCC) and 2 more (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Average concentration of ipilimumab at Day 42, Area under the concentration curve at Day 42 and 3 more. Started Jun 2020; status: terminated.
02
Drugs
ipilimumab
03
Conditions
melanomaurothelial carcinoma (UC)hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04311710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311710.